Video Experimental Relacionado
Updated: Jun 14, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
El inhibidor del factor XIIa de la albúmina humana recombinante Infestin-4 elimina la formación de trombos arteriales
Ina Hagedorn1, Stefan Schmidbauer, Irina Pleines
1University Clinic, University of Würzburg, 97080 Würzburg, Germany.
Circulation
|March 24, 2010
Resumen
Un nuevo inhibidor, rHA-Infestin-4, previene eficazmente la formación de trombos patológicos y el accidente cerebrovascular isquémico en modelos animales. Este inhibidor del factor XIIa ofrece una potente protección antitrombótica sin comprometer la hemostasis.
Área de la Ciencia:
- La bioquímica es la bioquímica.
- Farmacología Farmacología.
- Hematología Hematología.
Sus antecedentes:
- La coagulación de la sangre es un proceso vital para la hemostasis, pero también puede causar enfermedades trombóticas como infarto de miocardio y accidente cerebrovascular.
- El factor XII (FXII) juega un papel clave en la formación de trombos patológicos, pero no es esencial para la hemostasis normal.
- FXII es un objetivo terapéutico potencial para estrategias antitrombóticas seguras.
Objetivo del estudio:
- Investigar la eficacia de un nuevo inhibidor del Factor XIIa, rHA-Infestin-4, en la prevención de la trombosis patológica y los eventos isquémicos.
- Evaluar la seguridad de rHA-Infestin-4 mediante la evaluación de su impacto en la hemostasis.
Principales métodos:
- El ADN complementario de Infestin-4 se fusionó con la albúmina humana recombinante (rHA).
- Análisis in vitro de rHA-Infestin-4 para la inhibición del Factor XIIa y su efecto en el tiempo de tromboplastina parcial activado (aPTT) en plasma humano, de ratón y de rata.
- Estudios in vivo en ratones y ratas para evaluar la formación de trombos y la protección en modelos de accidente cerebrovascular isquémico, junto con ensayos de sangrado.
Principales resultados:
- rHA-Infestin-4 demostró una inhibición específica del Factor XIIa, prolongando la aPTT en múltiples especies.
- In vivo, el rHA-Infestin-4 impidió completamente la formación de trombos arteriales en ratones y ratas.
- rHA-Infestin-4 proporcionó una protección significativa en un modelo murino de accidente cerebrovascular isquémico mientras se mantenía la hemostasis normal.
Conclusiones:
- rHA-Infestin-4 es un potente inhibidor del Factor XIIa.
- Este agente ofrece una protección robusta contra los eventos isquémicos cardiovasculares y cerebrovasculares.
- rHA-Infestin-4 representa un prometedor candidato terapéutico para la terapia antitrombótica con un perfil de seguridad favorable con respecto a la hemostasis.
Videos de Conceptos Relacionados
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...